The shared role of oxidative stress and inflammation in major depressive disorder and nicotine dependence

Neuroscience and Biobehavioral Reviews

Volumn 37, Issue 8, 2013, Pages 1336-1345

  Nunes, Sandra Odebrecht Vargas ^a   Vargas, Heber Odebrecht ^a   Prado, Eduardo ^b   Barbosa, Decio Sabbatini ^a   de Melo, Luiz Picoli ^a   Moylan, Steven ^c   Dodd, Seetal ^b,c   Berk, Michael ^b,c,d,e,f  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e BARWON HEALTH   (Australia)

^f FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Dependence; Depression; Inflammation; Nicotine; Oxidative stress

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIOXIDANT; BILIRUBIN; C REACTIVE PROTEIN; CHEMOKINE; CYTOKINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; FIBRINOGEN; GAMMA GLUTAMYLTRANSFERASE; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; ISOPROSTANE DERIVATIVE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEOPTERIN; NICOTINIC RECEPTOR ALPHA4BETA2; PROSTAGLANDIN F2 ALPHA; SEROTONIN;

AUTOIMMUNE DISEASE; BRAIN FUNCTION; CELL ACTIVATION; CENTRAL NERVOUS SYSTEM DISEASE; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME SYNTHESIS; EPIGENETICS; GENE FUNCTION; GENETIC POLYMORPHISM; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INFLAMMATION; MAJOR DEPRESSION; NERVE DEGENERATION; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SMOKING; TOBACCO DEPENDENCE;

DEPENDENCE; DEPRESSION; INFLAMMATION; NICOTINE; OXIDATIVE STRESS;

BRAIN; DEPRESSIVE DISORDER, MAJOR; HUMANS; INFLAMMATION; OXIDATIVE STRESS; TOBACCO USE DISORDER;

EID: 84879715963     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2013.04.014     Document Type: Review

References (126)

1. Almeida O.P., Norman P., Hankey G.J., Jamrozik K., Flicker L. The association between C-reactive protein concentration and depression in later life is due to poor physical health: results from the Health in Men Study (HIMS). Psychol. Med. 2007, 37:1775-1786.
2. Asnis G.M., De La Garza R. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J. Clin. Gastroenterol. 2006, 40:322-335.
3. Asthana A., Johnson H.M., Piper M.E., Fiore M.C., Baker T.B., Stein J.H. Effects of smoking intensity and cessation on inflammatory markers in a large cohort of active smokers. Am. Heart J. 2010, 160:458-463.
4. Baldessarini R.J. The basis for amine hypotheses in affective disorders. A critical evaluation. Arch. Gen. Psychiatry 1975, 32:1087-1093.
5. Bateman A., Singh A., Kral T., Solomon S. The immune-hypothalamic-pituitary-adrenal axis. Endocr. Rev. 1989, 10:92-112.
6. Benowitz N.L. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin. Pharmacol. Ther. 2008, 83:531-541.
7. Benowitz N.L. Nicotine addiction. N. Engl. J. Med. 2010, 362:2295-2303.
8. Benton T., Staab J., Evans D.L. Medical co-morbidity in depressive disorders. Ann. Clin. Psychiatry 2007, 19:289-303.
9. Berger P.A., Faull K.F., Kilkowski J., Anderson P.J., Kraemer H., Davis K.L., Barchas J.D. CSF monoamine metabolites in depression and schizophrenia. Am. J. Psychiatry 1980, 137:174-180.
10. Berk M., Plein H., Ferreira D. Platelet glutamate receptor supersensitivity in major depressive disorder. Clin. Neuropharmacol. 2001, 24:129-132.
11. Berk M., Dodd S., Kauer-Sant'anna M., Malhi G.S., Bourin M., Kapczinski F., Norman T. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr. Scand. Suppl. 2007, 41-49.
12. Berk M. Should we be targeting smoking as a routine intervention?. Acta Neuropsychiatr. 2007, 19(2):131-132.
13. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., Yucel M., Gama C.S., Dodd S., Dean B., Magalhães P.V.S., Amminger P., McGorry P., Malhi G.S. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 2011, 35:804-817.
14. Berk M., Johansson S., Wray N.R., Williams L., Olsson C., Haavik J., Bjerkeset O. Glutamate cysteine ligase (GCL) and self reported depression: an association study from the HUNT. J. Affect. Disord. 2011, 131:207-213.
15. Breslau N., Novak S.P., Kessler R.C. Psychiatric disorders and stages of smoking. Biol. Psychiatry 2004, 55:69-76.
16. Breslau N., Schultz L., Johnson E., Peterson E., Davis G. Smoking and the risk of suicidal behavior: a prospective study of a community sample. Arch. Gen. Psychiatry 2005, 62(3):328-334.
17. Brody A.L., Mandelkern M.A., Jarvik M.E., Lee G.S., Smith E.C., Huang J.C., Bota R.G., Bartzokis G., London E.D. Differences between smokers and nonsmokers in regional gray matter volumes and densities. Biol. Psychiatry 2004, 55:77-84.
18. Bruijnzeel A.W. Tobacco addiction and the dysregulation of brain stress systems. Neurosci. Biobehav. Rev. 2012, 36:1418-1441.
19. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., McClay J., Mill J., Martin J., Braithwaite A., Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386-389.
20. Cataldo J.K., Prochaska J.J., Glantz S.A. Cigarette smoking is a risk factor for Alzheimer's disease: an analysis controlling for tobacco industry affiliation. J. Alzheimers Dis. 2010, 19(2):465-480. 10.3233/JAD-2010-1240.
21. Chen P., Jiang T., Ouyang J., Chen Y. Depression, another autoimmune disease from the view of autoantibodies. Med. Hypotheses 2009, 73:508-509.
22. Chung S., Sundar I.K., Hwang J.W., Yull F.E., Blackwell T.S., Kinnula V.L., Bulger M., Yao H., Rahman I. NF-κB inducing kinase, NIK mediates cigarette smoke/TNFα-induced histone acetylation and inflammation through differential activation of IKKs. PLoS ONE 2011, 6(8):e23488.
23. Cox L.S., Nollen N.L., Mayo M.S., Choi W.S., Faseru B., Benowitz N.L., Tyndale R.F., Okuyemi K.S., Ahluwalia J.S. Bupropion for smoking cessation in African American light smokers: a randomized controlled trial. J. Natl. Cancer Inst. 2012, 104:290-298.
24. Danese A., Moffitt T.E., Pariante C.M., Ambler A., Poulton R., Caspi A. Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch. Gen. Psychiatry 2008, 65(4):409-415.
25. Dani J.A., Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu. Rev. Pharmacol. Toxicol. 2007, 47:699-729.
26. Danner M., Kasl S.V., Abramson J.L., Vaccarino V. Association between depression and elevated C-reactive protein. Psychosom. Med. 2003, 65:347-356.
27. Danovitch I. The clinical assessment and treatment of nicotine dependence. Focus 2011, 9(1):15-24.
28. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
29. de Simone R., Ajmone-Cat M.A., Carnevale D., Carnevale L. Activation of α7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J. Neuroinflammation 2005, 2(1):4. 10.1186/1742-2094-2-4.
30. Dodd S., Brnabic A.J.M., Berk L., Fitzgerald P.B., de Castella A.R., Filia S., Filia K., Kelin K., Smith M., Montgomery W., Kulkarni J., Berk M. A prospective study of the impact of smoking on outcomes in bipolar and schizoaffective disorder. Compr. Psychiatry 2010, 51:504-509.
31. Dome P., Lazary J., Kalapos M.P., Rihmer Z. Smoking, nicotine and neuropsychiatric disorders. Neurosci. Biobehav. Rev. 2010, 34(3):295-342.
32. Douglas K.M., Taylor A.J., O'Malley P.G. Relationship between depression and C-reactive protein in a screening population. Psychosom. Med. 2004, 66:679-683.
33. Driver J.A., Beiser A., Au R., Kreger B., Splansky L.G., Kurth T., Kiel D.P., Lu K.P., Seshadri S.S., Wolf P. Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study. BMJ 2012, 344:e1442. 10.1136/bmj.e1442.
34. D'Souza M., Markou A. Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments. Addict. Sci. Clin. Pract. 2011, 6(1):4-16.
35. Durazzo T., Meyerhoff D., Nixon D. Chronic cigarette smoking: implications for neurocognition and brain neurobiology. Int. J. Environ. Res. Public Health 2010, 7:3760-3791.
36. Elovainio M., Aalto A.-M., Kivimäki M., Pirkola S., Sundvall J., Lönnqvist J., Reunanen A. Depression and C-reactive protein: population-based Health 2000 Study. Psychosom. Med. 2009, 71:423-430.
37. Fagerstrom K., Eissenberg T. Dependence on tobacco and nicotine products: a case for product-specific assessment. Nicotine Tob. Res. 2012, 10.1093/ntr/nts007.
38. Ford D.E., Erlinger T.P. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch. Intern. Med. 2004, 164:1010-1014.
39. Forlenza M.J., Miller G.E. Increased serum levels of 8-hydroxy-2'-deoxyguanosine in clinical depression. Psychosom. Med. 2006, 68:1-7.
40. Federico A., Cardaioli E., Da Pozzo P., Formichi P., Gallus G.N., Radi E. Mitochondria, oxidative stress and neurodegeneration. J. Neurol. Sci. 2012, 322:254-282.
41. Gardner A., Boles R.G. Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35(3):730-743.
42. Garrabou G., Inoriza J.M., Morén C., Oliu G., Miró Ò., Marti M.J., Cardellach F. Mitochondrial injury in human acute carbon monoxide poisoning: the effect of oxygen treatment. J. Environ. Sci. Health C 2011, 29:32-51.
43. Gimeno D., Kivimäki M., Brunner E.J., Elovainio M., De Vogli R., Steptoe A., Kumari M., Lowe G.D.O., Rumley A., Marmot M.G., Ferrie J.E. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol. Med. 2009, 39(3):413-423.
44. Goldstein B.I., Kemp D.E., Soczynska J.K., McIntyre R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J. Clin. Psychiatry 2009, 70(8):1078-1090.
45. Gons R.A., van Norden A.G., de Laat K.F., van Oudheusden L.J., van Uden I.W., Zwiers M.P., Norris D.G., de Leeuw F.E. Cigarette smoking is associated with reduced microstructural integrity of cerebral white matter. Brain 2011, 134(Pt 7):2116-2124.
46. Halliwell B. Oxidative stress and neurodegeneration: where are we now?. J. Neurochem. 2006, 97:1634-1658.
47. Hamer M., Molloy G.J., de Oliveira C., Demakakos P. Leisure time physical activity, risk of depressive symptoms, and inflammatory mediators: the English Longitudinal Study of Ageing. Psychoneuroendocrinology 2009, 34:1050-1055.
48. Hamer M., Molloy G.J., de Oliveira C., Demakakos P. Persistent depressive symptomatology and inflammation: to what extent do health behaviours and weight control mediate this relationship?. Brain Behav. Immun. 2009, 23:413-418.
49. Hashimoto K. The role of glutamate on the action of antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:1558-1568.
50. Heim C., Newport D.J., Heit S., Graham Y.P., Wilcox M., Bonsall R., Miller A.H., Nemeroff C.B. Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA 2000, 284:592-597.
51. Henje Blom E., Lekander M., Ingvar M., Åsberg M., Mobarrez F., Serlachius E. Pro-inflammatory cytokines are elevated in adolescent females with emotional disorders not treated with SSRIs. J. Affect. Disord. 2012, 136:716-723.
52. Ho Y.-S., Yang X., Yeung S.-C., Chiu K., Lau C.-F., Tsang A.W.-T., Mak C.-W., Chang R.C.-C. Cigarette smoking accelerated brain aging and induced pre-Alzheimer-like neuropathology in rats. PLoS ONE 2012, 7(5):e36752.
53. Holsboer F., Spengler D., Heuser I. The role of corticotropin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia. Prog. Brain Res. 1992, 93:385-417.
54. Jamal M., Willem Van der Does A.J., Cuijpers P., Penninx B.W.J.H. Association of smoking and nicotine dependence with severity and course of symptoms in patients with depressive or anxiety disorder. Drug Alcohol Depend. 2012, 126(1/2):138-146.
55. Kapczinski F., Vieta E., Andreazza A.C., Frey B.N., Gomes F.A., Tramontina J., Kauer-Sant'anna M., Grassi-Oliveira R., Post R.M. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci. Biobehav. Rev. 2008, 32(4):675-692.
56. Kauer J.A., Malenka R.C. Synaptic plasticity and addiction. Nat. Rev. Neurosci. 2007, 8:844-858.
57. Kobrosly R., van Wijngaarden E. Associations between immunologic, inflammatory, and oxidative stress markers with severity of depressive symptoms: an analysis of the 2005-2006 National Health and Nutrition Examination Survey. Neurotoxicology 2010, 31:126-133.
58. Lambert G., Johansson M., Agren H., Friberg P. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch. Gen. Psychiatry 2000, 57:787-793.
59. Laske C., Zank M., Klein R., Stransky E., Batra A., Buchkremer G., Schott K. Autoantibody reactivity in serum of patients with major depression, schizophrenia and healthy controls. Psychiatry Res. 2008, 158:83-86.
60. Lasser K., Boyd J.W., Woolhandler S., Himmelstein D.U., McCormick D., Bor D.H. Smoking and mental illness: a population-based prevalence study. JAMA 2000, 284(20):2606-2610.
61. Launay J.M., Del Pino M., Chironi G., Callebert J., Peoc'h K., Megnien J.L., Mallet J., Simon A., Rendu F. Smoking induces long-lasting effects through a monoamine-oxidase epigenetic regulation. PLoS ONE 2009, 4:e7959.
62. Lehto S.M., Niskanen L., Miettola J., Tolmunen T., Viinamäki H., Mäntyselkä P. Serum anti-inflammatory markers in general population subjects with elevated depressive symptoms. Neurosci. Lett. 2010, 484:201-205.
63. Lehto S.M., Niskanen L., Herzig K.-H., Tolmunen T., Huotari A., Viinamäki H., Koivumaa-Honkanen H., Honkalampi K., Ruotsalainen H., Hintikka J. Serum chemokine levels in major depressive disorder. Psychoneuroendocrinology 2010, 35:226-232.
64. Leonard B., Myint K. Inflammation and depression: is there a causal connection with dementia?. Neurotox Res. 2006, 10(2):149-160.
65. Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci. Biobehav. Rev. 2012, 36(12):764-785.
66. Leventhal A.M., Kahler C.W., Ray L.A., Zimmerman M. Refining the depression-nicotine dependence link: patterns of depressive symptoms in psychiatric outpatients with current, past, and no history of nicotine dependence. Addict. Behav. 2009, 34(3):297-303.
67. Liukkonen T., Silvennoinen-Kassinen S., Jokelainen J., Räsänen P., Leinonen M., Meyer-Rochow V.B., Timonen M. The association between C-reactive protein levels and depression: results from the northern Finland 1966 birth cohort study. Biol. Psychiatry 2006, 60:825-830.
68. Maes M., Meltzer H., Jacobs J., Suy E., Calabrese J., Minner B., Raus J. Autoimmunity in depression: increased antiphospholipid autoantibodies. Acta Psychiatr. Scand. 1993, 87(3):160-166.
69. Maes M., Yirmyia R., Noraberg J., Brene S., Hibbeln J., Perini G., Kubera M., Bob P., Lerer B., Maj M. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab. Brain Dis. 2009, 24:27-53.
70. Maes M., Leonard B., Fernandez A., Kubera M., Nowak G., Veerhuis R., Gardner A., Ruckoanich P., Geffard M., Altamura C., Galecki P., Berk M. (Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: from antioxidants to kinase inhibitors. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35(3):659-663.
71. Maes M., Ringel K., Kubera M., Berk M., Rybakowski J. Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. J. Affect. Disord. 2012, 136:386-392.
72. Maes M., Fišar Z., Medina M., Scapagnini G., Nowak G., Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates-Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012, 20(3):127-150.
73. Maes M., Berk M., Goehler L., Song C., Anderson G., Gaecki P., Leonard B. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med. 2012, 10:66.
74. Malhi G.S., Berk M. Does dopamine dysfunction drive depression?. Acta Psychiatr. Scand. Suppl. 2007, 433:116-124.
75. Malone K.M., Waternaux C., Haas G.L., Cooper T.B., Li S., Mann J.J. Cigarette smoking, suicidal behavior, and serotonin function in major psychiatric disorders. Am. J. Psychiatry 2003, 160:773-779.
76. Manji H., Kato T.D., Prospero N.A., Ness S., Beal M.F., Krams M., Chen G. Impaired mitochondrial function in psychiatric disorders. Nat. Rev. Neurosci. 2012, 13(5):293-307.
77. McNally L., Bhagwagar Z., Hannestad J. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr. 2008, 13:501-510.
78. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65:732-741.
79. Miller G.E., Cole S.W. Clustering of depression and inflammation in adolescents previously exposed to childhood adversity. Biol. Psychiatry 2012, 72(1):34-40.
80. Miró O., Alonso J.R., Jarretra D., Casademont J., Urbano-Marquez A., Cardellach F. Smoking disturbs mitochondrial respiratory chain function and enhances lipid peroxidation on human circulating lymphocytes. Carcinogenesis 1999, 20(7):1331-1336.
81. Monji A., Kato T., Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin. Neurosci. 2009, 63:257-265.
82. Moylan S., Maes M., Wray N.R., Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol. Psychiatry 2012, 10.1038/mp.2012.33.
83. Müller N., Schwarz M.J. A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2008, 258(Suppl. 2):97-106.
84. Muñoz P., Huenchuguala S., Paris I., Villa M., Cuevas C., Caviede P., Segura-Aguilar J., Tizabi Y. Protective effects of nicotine against aminochrome-induced toxicity in substantia nigra derived cells: implications for Parkinson's disease. Neurotox Res. 2012, 22:177-180.
85. Myint A.-M., Kim Y.K., Verkerk R., Scharpa S., Steinbusch H., Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect. Disord. 2007, 98:143-151.
86. Nakamura T., Lipton S.A. Redox modulation by S-nitrosylation contributes to protein misfolding, mitochondrial dynamics, and neuronal synaptic damage in neurodegenerative diseases. Cell Death Differ. 2011, 18(9):1478-1486.
87. Nemeroff C.B., Simon J.S., Haggerty J.J.Evans D.L. Antithyroid antibodies in depressed patients. Am. J. Psychiatry 1985, 142:840-843.
88. Nemeroff C.B., Vale W.W. The neurobiology of depression: in roads to treatment and new drug discovery. J. Clin. Psychiatry 2005, 66(Suppl. 7):5-13.
89. Nunes S.O.V., Watanabe M.A.E., Morimoto H.K., Moriya R., Reiche E.M.V. The impact of childhood sexual abuse on activation of immunological and neuroendocrine response. Aggress. Violent Behav. 2010, 15(6):440-445.
90. Nunes S.O.V., Vargas H.O., Brum J., Prado E., Vargas M.M., de Castro M.R.P., Dodd S., Berk M. A comparison of inflammatory markers in depressed and nondepressed smokers. Nicotine Tob. Res. 2012, 14:540-546.
91. Nunnari J., Suomalainen A. Mitochondria: in sickness and in health. Cell 2012, 148:1145-1159.
92. Pariante C.M., Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry 2001, 49:391-404.
93. Patton G.C., Carlin J.B., Coffey C., Wolfe R., Hibbert M., Bowes G. Depression, anxiety, and smoking initiation: a prospective study over 3 years. Am. J. Public Health 1998, 88(10):1518-1522.
94. Pasco J.A., Williams L.J., Jacka F.N., Ng F., Henry M.J., Nicholson G.C., Kotowicz M.A., Berk M. Tobacco smoking as a risk factor for major depressive disorder: population-based study. Br. J. Psychiatry 2008, 193:322-326.
95. Pasco J.A., Nicholson G.C., Williams L.J., Jacka F.N., Henry M.J., Kotowicz M.A., Schneider H.G., Leonard B.E., Berk M. Association of high-sensitivity C-reactive protein with de novo major depression. Br. J. Psychiatry 2010, 197:372-377.
96. Pedersen W., von Soest T. Smoking, nicotine dependence and mental health among young adults: a 13-year population-based longitudinal study. Addiction 2009, 104(1):129-137.
97. Pike J.L., Irwin M.R. Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder. Brain Behav. Immun. 2006, 20:169-174.
98. Quaak M., van Schayck C.P., Knaapen A.M., van Schooten F.J. Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases?. Eur. Respir. J. 2009, 33(3):468-480.
99. Queiroga C.S.F., Almeida A.S., Vieira H.L.A. Carbon monoxide targeting mitochondria. Biochem. Res. Int. 2012, 1-9.
100. Raison C.L., Miller A.H. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am. J. Psychiatry 2003, 160:1554-1565.
101. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006, 27:24-31.
102. Rohleder N., Kirschbaum C. The hypothalamic-pituitary-adrenal (HPA) axis in habitual smokers. Int. J. Psychophysiol. 2006, 59:236-243.
103. Rueff-Barroso C.R., Trajano E.T., Alves J.N., Paiva R.O., Lanzetti M. Organ-related cigarette smoke-induced oxidative stress is strain-dependent. Med. Sci. Monit. 2010, 16(7):BR218-BR226.
104. Rytilä P., Rehn T., Ilumets H., Rouhos A., Sovijärvi A., Myllärniemi M., Kinnula V.L. Increased oxidative stress in asymptomatic current chronic smokers and GOLD stage 0 COPD. Respir. Res. 2006, 7:69.
105. Salim S., Chugh G., Asghar M. Inflammation in anxiety. Adv. Protein Chem. Struct. Biol. 2012, 88:1-25. 10.1016/B978-0-12-398314-5.00001-5.
106. Saveanu R.V., Nemeroff C.B. Etiology of depression: genetic and environmental factors. Psychiatr. Clin. N. Am. 2012, 35(1):51-71.
107. Savitz J., Drevets W.C. Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci. Biobehav. Rev. 2009, 33:699-771.
108. Schroeder S.A. Depression, smoking, and heart disease: how can psychiatrists be effective?. Am. J. Psychiatry 2011, 168(9):876-878.
109. Seppet E., Gruno M., Peetsalu A., Gizatullina Z., Nguyen H.P., Vielhaber S., Wussling M.H.P., Trumbeckaite S., Arandarcikaite O., Jerzembeck D., Sonnabend M., Jegorov K., Zierz S., Striggow F., Gellerich F.N. Mitochondria and energetic depression in cell pathophysiology. Int. J. Mol. Sci. 2009, 10:2252-2303.
110. Sies H. Oxidative stress: from basic research to clinical application. J. Med. 1991, 91(3):S31-S35.
111. Sies H. Oxidative stress: oxidants and antioxidants. Exp. Physiol. 1997, 82:291-295.
112. Sieminska A., Buczkowski K., Jassem E., Tkacz E. Lack of association between serotonin transporter gene polymorphism 5-HTTLPR and smoking among Polish population: a case-control study. BMC Med. Genet. 2008, 9:76. 10.1186/1471-2350-9-76.
113. Smith R.S. The macrophage theory of depression. Med. Hypotheses 1991, 35:298-306.
114. Stockmeier C.A. Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. J. Psychiatr. Res. 2003, 37:357-373.
115. Su S., Miller A.H., Snieder H., Bremner J., Ritchie J., Maisano C., Jones L., Murrah N.V., Goldberg J., Vaccarino V. Common genetic contributions to depressive symptoms and inflammatory markers in middle-aged men: the Twins Heart Study. Psychosom. Med. 2009, 71:152-158.
116. Sublette M.E., Galfalvy H.C., Fuchs D., Lapidus M., Grunebaum M.F., Oquendo M.A., Mann J.J., Postolache T.T. Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav. Immun. 2011, 25:1272-1278.
117. Swan G., Lessov-Schlaggar C. The effects of tobacco smoke and nicotine on cognition and the brain. Neuropsychol. Rev. 2007, 17:259-273.
118. Talhout R., Opperhuizen A., van Amsterdam J.G. Role of acetaldehyde in tobacco smoke addiction. Eur. Neuropsychopharmacol. 2007, 17(10):627-636.
119. Uher R. The role of genetic variation in the causation of mental illness: an evolution-informed framework. Mol. Psychiatry 2009, 14:1072-1082.
120. van der Vaart H., Postma D.S., Timens W., ten Hacken N.H.T. Acute effects of cigarette smoke on inflammation and oxidative stress: a review. Thorax 2004, 59:713-721.
121. Vassalle C., Novembrino C., Maffei S., Sciarrino R., De Giuseppe R., Vigna L., de Liso F., Mercuri A., Bamonti F. Determinants of oxidative stress related to gender: relevance of age and smoking habit. Clin. Chem. Lab. Med. 2011, 49(9):1509-1513.
122. Watanabe M.A.E., Nunes S.O.V., Amarante M.K., Guembarovski R.L., Oda J.M.M., Lima K.W.A.D., Fungaro M.H.P. Genetic polymorphism of serotonin transporter 5-HTTLPR: involvement in smoking behaviour. J. Genet. 2011, 90:179-185.
123. Yager S., Forlenza M.J., Miller G.E. Depression and oxidative damage to lipids. Psychoneuroendocrinology 2010, 35:1356-1362.
124. Yanbaeva D.G., Dentener M.A., Creutzberg E.C., Wesseling G., Wouters E.F.M. Systemic effects of smoking. Chest 2007, 131:1557-1566.
125. Zhang X., Salmeron B.J., Ross T.J., Geng X., Yang Y., Stein E.A. Factors underlying prefrontal and insula structural alterations in smokers. Neuroimage 2011, 54:42-48.
126. Ziedonis D., Hitsman B., Beckham J.C., Zvolensky M., Adler L.E., Audrain-McGovern J., Breslau N., Brown R.A., George T.P., Williams J., Calhoun P.S., Riley W.T. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob. Res. 2008, 10(12):1691-1715.